Literature DB >> 35651316

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia.

Yonglan Liu1, Hyunbum Jang2, Mingzhen Zhang2, Chung-Jung Tsai2, Ryan Maloney1, Ruth Nussinov3.   

Abstract

BCR-ABL drives chronic myeloid leukemia (CML). BCR binding to GRB2 transduces signaling via the Ras/MAPK pathway. Despite considerable data confirming the binding, molecular-level understanding of exactly how the two proteins interact, and, especially, what are the determinants of the specificity of the SH2GRB2 domain-phosphorylated BCR (pBCR) recognition are still open questions. Yet, this is vastly important for understanding binding selectivity, and for predicting the phosphorylated receptors, or peptides, that are likely to bind. Here, we uncover these determinants and ascertain to what extent they relate to the affinity of the interaction. Toward this end, we modeled the complexes of the pBCR and SH2GRB2 and other pY/Y-peptide-SH2 complexes and compared their specificity and affinity. We observed that pBCR's 176FpYVNV180 motif is favorable and specific to SH2GRB2, similar to pEGFR, but not other complexes. SH2GRB2 contains two binding pockets: pY-binding recognition pocket triggers binding, and the specificity pocket whose interaction is governed by N179 in pBCR and W121 in SH2GRB2. Our proposed motif with optimal affinity to SH2GRB2 is E/D-pY-E/V-N-I/L. Collectively, we provide the structural basis of BCR-ABL recruitment of GRB2, outline its specificity hallmarks, and delineate a blueprint for prediction of BCR-binding scaffolds and for therapeutic peptide design.
Copyright © 2022 Biophysical Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35651316      PMCID: PMC9279350          DOI: 10.1016/j.bpj.2022.05.030

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   3.699


  80 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.

Authors:  Akriti Kharbanda; David M Walter; Andrea A Gudiel; Nancy Schek; David M Feldser; Eric S Witze
Journal:  Sci Signal       Date:  2020-03-03       Impact factor: 8.192

3.  The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.

Authors:  R P Million; R A Van Etten
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

4.  Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Authors:  Maro Ohanian; Ana Tari Ashizawa; Guillermo Garcia-Manero; Naveen Pemmaraju; Tapan Kadia; Elias Jabbour; Farhad Ravandi; Gautam Borthakur; Michael Andreeff; Marina Konopleva; Miranda Lim; Sherry Pierce; Susan O'Brien; Yesid Alvarado; Srdan Verstovsek; William Wierda; Hagop Kantarjian; Jorge Cortes
Journal:  Lancet Haematol       Date:  2018-03-14       Impact factor: 18.959

5.  Defining the specificity space of the human SRC homology 2 domain.

Authors:  Haiming Huang; Lei Li; Chenggang Wu; David Schibli; Karen Colwill; Sucan Ma; Chengjun Li; Protiva Roy; Krystina Ho; Zhou Songyang; Tony Pawson; Youhe Gao; Shawn S-C Li
Journal:  Mol Cell Proteomics       Date:  2007-10-22       Impact factor: 5.911

Review 6.  The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Authors:  Paul W Manley; Louise Barys; Sandra W Cowan-Jacob
Journal:  Leuk Res       Date:  2020-09-29       Impact factor: 3.156

7.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.

Authors:  Z Songyang; S E Shoelson; J McGlade; P Olivier; T Pawson; X R Bustelo; M Barbacid; H Sabe; H Hanafusa; T Yi
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

8.  BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.

Authors:  Su Chu; Liang Li; Harjeet Singh; Ravi Bhatia
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

9.  The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1.

Authors:  Yi-Chun Liao; Lizhen Si; Ralph W deVere White; Su Hao Lo
Journal:  J Cell Biol       Date:  2006-12-26       Impact factor: 10.539

10.  Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.

Authors:  Afsar Ali Mian; Isabella Haberbosch; Hazem Khamaisie; Abed Agbarya; Larissa Pietsch; Elizabeh Eshel; Dally Najib; Claudia Chiriches; Oliver Gerhard Ottmann; Oliver Hantschel; Ricardo M Biondi; Martin Ruthardt; Jamal Mahajna
Journal:  Ann Hematol       Date:  2021-06-10       Impact factor: 3.673

View more
  1 in total

1.  Allosteric regulation of autoinhibition and activation of c-Abl.

Authors:  Yonglan Liu; Mingzhen Zhang; Chung-Jung Tsai; Hyunbum Jang; Ruth Nussinov
Journal:  Comput Struct Biotechnol J       Date:  2022-08-11       Impact factor: 6.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.